Difference between revisions of "Procarbazine (Matulane)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:DNA synthesis inhibitors" to "Category:Human DNA synthesis inhibitors") |
m |
||
| Line 16: | Line 16: | ||
==Diseases for which it was used== | ==Diseases for which it was used== | ||
| − | *[[Diffuse large B-cell lymphoma]] | + | *[[Diffuse large B-cell lymphoma - historical|Diffuse large B-cell lymphoma]] |
| + | *[[Non-small cell lung cancer - historical|Non-small cell lung cancer]] | ||
| + | *[[Small cell lung cancer - historical|Small cell lung cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 45: | Line 47: | ||
[[Category:Glioblastoma medications]] | [[Category:Glioblastoma medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
| − | + | [[Category:Low-grade glioma medications]] | |
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
| + | |||
| + | [[Category:Diffuse large B-cell lymphoma medications (historic)]] | ||
| + | [[Category:Non-small cell lung cancer medications (historic)]] | ||
| + | [[Category:Small cell lung cancer medications (historic)]] | ||
[[Category:FDA approved in 1969]] | [[Category:FDA approved in 1969]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 01:41, 29 April 2022
General information
Class/mechanism: Hydrazine derivative, alkylator; exact mechanism not understood. May inhibit transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis. May also directly damage DNA.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Anaplastic glioma
- CNS lymphoma
- Follicular lymphoma
- Glioblastoma
- Hodgkin lymphoma
- Low-grade glioma
- Mantle cell lymphoma
Diseases for which it was used
Patient drug information
- Procarbazine (Matulane) patient drug information (Chemocare)[3]
- Procarbazine (Matulane) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 7/22/1969: Initial FDA approval
Also known as
- Code names: NCI-C01810, Ro 4-6467/1
- Generic names: ibenzmethyzin hydrochloride, ibenzmethyzine hydrochloride, P-Carbazine, procarbazine hydrochloride
- Brand names: Indicarb, Matulane, Natulan, Natulanar, P-Carzine
References
Categories:
- Drugs
- Oral medications
- Triazenes
- Alkylating agents
- Human DNA synthesis inhibitors
- Anaplastic glioma medications
- CNS lymphoma medications
- Follicular lymphoma medications
- Glioblastoma medications
- Hodgkin lymphoma medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Diffuse large B-cell lymphoma medications (historic)
- Non-small cell lung cancer medications (historic)
- Small cell lung cancer medications (historic)
- FDA approved in 1969
- WHO Essential Cancer Medicine